Tournament: Greenhill | Round: 1 | Opponent: Denton Guyer SB | Judge: David Dosch
CP: France, Germany, Sweden, and Italy should:
substantially increase COVID vaccine production to meet the global demand
sign bilateral intellectual property licensing contracts with low and middle-income countries to share vaccines
donate all necessary vaccines at no cost to low and middle-income nations unable to license intellectual property rights
Global donations and increased domestic production solve
Yamey 21 ~Gavin, Directs the Center for Policy Impact in Global Health at Duke University in Durham, North Carolina. "Rich Countries Should Tithe Their Vaccines" https://www.nature.com/articles/d41586-021-00470-9~~
As I write this, 191 million vaccination shots against COVID-19 have been
AND
collectively to boost vaccinations. It is self-defeating to act otherwise.
Eliminating IPR for vaccines gives China a massive competitive edge on innovation broadly – tanks pharma, undermines pandemic response, and tech leadership – BUT domestic production and distribution solves
Okutsu and Sharma 21 ~Akane, staff writer for Nikkei International, and Kiran, LPC, The College of Law, Guildford, 1997 BA (Hons), Law, Gonville and Caius College, Cambridge University, 1996. "Vaccine Patent Waiver: COVID Stopper or Innovation Killer?" https://asia.nikkei.com/Spotlight/Coronavirus/COVID-vaccines/Vaccine-patent-waiver-COVID-stopper-or-innovation-killer~~
Western pharmaceutical companies are telling U.S. officials that they fear exposing their
AND
Health Organization's~ COVAX initiative to purchase and distribute vaccines to developing countries."
Biopharma innovation is key to overall competitiveness – US still has a razor thin lead but IP is uniquely key
Ezell 20 ~Stephen Ezell, Director of Global Innovation Policy at the Information Technology and Innovation Foundation (ITIF). "Ensuring U.S. Biopharmaceutical Competitiveness." 7/16/20. https://itif.org/publications/2020/07/16/ensuring-us-biopharmaceutical-competitiveness~~
Nations are competing for increased market share in a wide array of advanced-innovation
AND
time for Washington to articulate and embrace a robust national biopharmaceutical competitiveness strategy.
Kroenig and Gopalaswamy 18, *Associate Professor of Government and Foreign Service at Georgetown University and Deputy Director for Strategy in the Scowcroft Center for Strategy and Security at the Atlantic Council. Director of the South Asia Center at the Atlantic Council. He holds a PhD in mechanical engineering with a specialization in numerical acoustics from Trinity College, Dublin. (Matthew and Bharath, 11-12-2018, "Will disruptive technology cause nuclear war?", Bulletin of the Atomic Scientists, https://thebulletin.org/2018/11/will-disruptive-technology-cause-nuclear-war/)
Rather, we should think more broadly about how new technology might affect global politics
AND
second-strike capabilities, but to preserve prevailing power balances more broadly.